Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- DOI
- 10.1007/s40257-025-00932-0
- Published
- 2025-04-11
- Container
- American Journal of Clinical Dermatology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s40257-025-00932-0,
title = {Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment},
author = {Brett King and Arash Mostaghimi and Yutaka Shimomura and Bianca Maria Piraccini and Ulrike Blume-Peytavi and Angelina Sontag and Yves Dutronc and Karen Denning and Jill Kolodsick and Xiaoyu Lu and Ayush Srivastava and Rodney Sinclair},
year = {2025},
journal = {American Journal of Clinical Dermatology},
doi = {10.1007/s40257-025-00932-0},
url = {https://doi.org/10.1007/s40257-025-00932-0}
}RIS
TY - JOUR TI - Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment AU - Brett King AU - Arash Mostaghimi AU - Yutaka Shimomura AU - Bianca Maria Piraccini AU - Ulrike Blume-Peytavi AU - Angelina Sontag AU - Yves Dutronc AU - Karen Denning AU - Jill Kolodsick AU - Xiaoyu Lu AU - Ayush Srivastava AU - Rodney Sinclair PY - 2025 JO - American Journal of Clinical Dermatology DO - 10.1007/s40257-025-00932-0 UR - https://doi.org/10.1007/s40257-025-00932-0 ER -
APA
King, B., Mostaghimi, A., Shimomura, Y., Piraccini, B. M., Blume-Peytavi, U., Sontag, A., Dutronc, Y., Denning, K., Kolodsick, J., Lu, X., Srivastava, A., & Sinclair, R. (2025). Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-025-00932-0
Source records
- crossref · retrieved 2026-09-27T01:11:27.561Z